Premium
Leukaemic relapse of donor origin after allogeneic bone marrow transplantation from a donor who later developed bronchogenic carcinoma
Author(s) -
Au W. Y.,
Chan E. C.,
Siu L. L. P.,
Lau T. C. M.,
Lie A. K. W.,
Ma S. K.,
Kwong Y. L.
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2002.03925.x
Subject(s) - medicine , malignancy , clone (java method) , bone marrow , transplantation , myeloid , oncology , immunology , biology , dna , genetics
Summary. Donor‐derived leukaemia is exceptional after allogeneic bone marrow transplantation (BMT). A woman with chronic myeloid leukaemia received an allogeneic BMT from a human leucocyte antigen‐identical brother. The donor, a 50‐year‐old non‐smoker, died of squamous cell bronchogenic carcinoma 1 year later. At 4 years post BMT, the patient became BCR/ABL positive and relapsed with acute myeloid leukaemia, which was shown to be donor‐derived cytogenetically and molecularly. Retrospective analysis showed that the donor‐leukaemic clone had started to evolve as early as 6 months post BMT. Sequencing of p53 ruled out Li–Fraumeni syndrome. Predisposition to malignancy might be an underlying mechanism of donor‐cell leukaemia.